Medical Device News Magazine

Growth in Use of Proton Therapy for Treating Wider Variety of Conditions | According to New Study Published in Red Journal Reveals Growth

Analysis of NAPT member survey data shows proportional drop in use of proton therapy for prostate cancer as treatment increases for breast, mouth and throat, and gastrointestinal cancers

About Medical Device News Magazine

About Medical Device News Magazine. We are a digital publication founded in 2008 located in the United States.

Advertise with Medical Device News Magazine! Join Our #1 Family of Advertisers!

We pride ourselves on being the best-kept secret when it comes to distributing your news! Our unique digital approach enables us to circulate your...

Proton Therapy

The National Association for Proton Therapy (NAPT), the nation’s leading organization dedicated to increasing patient access to one of the most advanced cancer treatments, today announced the publication of a study in the International Journal of Radiation Oncology-Biology-Physics (Red Journal) that examines the use of proton therapy to treat a growing number of conditions and tumor sites.

Based on NAPT member survey data and other sources, “Temporal Evolution and Diagnostic Diversification of Patients Receiving Proton Therapy in the United States: A Ten-Year Trend Analysis (2012-21) from the National Association for Proton Therapy” largely debunks the misperception that proton therapy is used primarily as a treatment for prostate cancer.

Study Reports

The study reports that there is “a clear and pressing need for accurate data regarding the number of patients treated with protons for various diagnoses,” which is useful “to help evaluate accrual to these trials and design new trials, and to help guide health policy decisions, rather than to base those decisions on speculation or legacy and outdated data.”

Study Author Comments

“The great news from this study is that more patients are able to access this advanced, precise form of cancer treatment,” said the study’s author, William F. Hartsell, MD, former Medical Director at the Northwestern Medicine Chicago Proton Center. “This is especially important for certain patients. For example, three times as many children are now able to receive this more targeted type of treatment compared to 10 years ago. As more studies have shown benefits for proton therapy, there has also been an increase in the use of proton therapy for certain other cancer types, such as breast cancer, mouth and throat cancers, and gastrointestinal cancers.”

NAPT Executive Director Jennifer Maggiore Remarks

“The use of proton therapy is evolving, and the types of patients treated is changing based on a growing body of evidence and clinical research. Our members are committed to research that contributes to improving outcomes for cancer patients. And while developing research is challenging with limited availability of the technology and restrictive commercial insurance policies, NAPT will continue to encourage cooperative research and innovation to advance the appropriate and cost-effective utilization of proton therapy.”

Number of Patients Receiving Proton Therapy Increases

As the number of patients receiving proton therapy increased from 5,377 in 2012 to 15,829 in 2021, a greater proportional increase was found among more complex conditions such as breast, cancers of the head and neck, and gastrointestinal tumors. From 2012-2021, the proportional mix of conditions treated by proton therapy changed as follows, by cancer type:

  • Breast: Increased from 1.7% to 9.2%
  • GI Tract: Increased from 3.2% to 7.0%
  • Head and Neck: Increased from 5.9% to 14.5%
  • Prostate: Decreased from 43.4% to 25.0%

Prostate Cancers Treated

The number of prostate cancer patients treated with proton therapy remained stable, but the proportion relative to the total number of proton patients treated decreased – from 43.4% to 25.0%

Worldwide Centers

The study also noted an increasing number of proton facilities operating outside the United States. There are nearly 110 protons centers worldwide, with more in the planning or construction phases. These include three proton centers in the Netherlands, with a national population of only 17 million. The study attributes the increase in proton therapy availability to the development of smaller facilities (1-2 rooms) compared to larger centers (3-5 treatment rooms), and to the “increasing acceptance that achieving dosimetric superiority in reducing and avoiding unnecessary radiation dose to organs-at-risk is a universal and foundational goal based on first principles of therapeutic radiation delivery.”

“It is interesting to note that proton therapy development is increasing worldwide due to the more affordable single room centers and the increasing acceptance of the value of avoiding unnecessary radiation to healthy tissue,” said Maggiore. “As the number of conditions treated expands in number and variety, proton therapy continues to gain acceptance and recognition as an increasing number of patients experience this life-saving, life-changing treatment.”

 

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Other News

Shoulder Innovations Further Strengthens IP Portfolio in Key Areas with Recent Patent Grants

"These recent grants further strengthen key patent families that are foundational to our technology, and we are pleased the USPTO continues to recognize our meaningful innovation in the shoulder arthroplasty segment," said Rob Ball, CEO of Shoulder Innovations. "This noteworthy expansion of our IP position represents the culmination of over 10 years of research and development, and we are proud of our team for their continued dedication to creating practical solutions for shoulder surgeons and advancing patient outcomes."

Radical Catheter Technologies Presents Analysis of Disruptive, Recently FDA-Cleared Endovascular Technology at the Society of NeuroInterventional Surgery 21st Annual Meeting

This new catheter, the first product commercialized from this novel technology platform, is designed to enable access to the blood vessels in the brain for both femoral and radial access. A multi-center analysis of this disruptive technology is being presented today at Society of NeuroInterventional Surgery 21st annual meeting. In addition, the Company confirmed the closing of a $20 million financing round led by NeuroTechnology Investors, which will be used to scale the company and expand the Radical platform notes Radical Catheter Technologies.

Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution

“With DRIVEWIRE, our design goal was to bring new levels of access and control to the interventional suite while improving best-in-class guidewires,” comments Giora Kornblau, Chief Technology Officer at Rapid Medical. “When physicians are looking for technologies that increase the clinical possibilities and safety for the patient, we want Rapid to be the first place they look.”